Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

448 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA).
Preudhomme C, Sagot C, Boissel N, Cayuela JM, Tigaud I, de Botton S, Thomas X, Raffoux E, Lamandin C, Castaigne S, Fenaux P, Dombret H; ALFA Group. Preudhomme C, et al. Among authors: thomas x. Blood. 2002 Oct 15;100(8):2717-23. doi: 10.1182/blood-2002-03-0990. Blood. 2002. PMID: 12351377 Free article.
Timed sequential chemotherapy for advanced acute myeloid leukemia.
Archimbaud E, Leblond V, Fenaux P, Dombret H, Cordonnier C, Dreyfus F, Cony-Makhoul P, Tilly H, Troussard X, Auzanneau G, Thomas X, Ffrench M, Marie JP. Archimbaud E, et al. Among authors: thomas x. Hematol Cell Ther. 1996 Apr;38(2):161-7. doi: 10.1007/s00282-996-0161-2. Hematol Cell Ther. 1996. PMID: 8931997 Clinical Trial.
Clinical and biological characteristics of adult de novo and secondary acute myeloid leukemia with balanced 11q23 chromosomal anomaly or MLL gene rearrangement compared to cases with unbalanced 11q23 anomaly: confirmation of the existence of different entities with 11q23 breakpoint.
Archimbaud E, Charrin C, Magaud JP, Campos L, Thomas X, Fière D, Rimokh R. Archimbaud E, et al. Among authors: thomas x. Leukemia. 1998 Jan;12(1):25-33. doi: 10.1038/sj.leu.2400853. Leukemia. 1998. PMID: 9436917
Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial).
Thomas X, Fenaux P, Dombret H, Delair S, Dreyfus F, Tilly H, Vekhoff A, Cony-Makhoul P, Leblond V, Troussard X, Cordonnier C, de Revel T, Simon M, Nicolini F, Stoppa AM, Janvier M, Bordessoule D, Rousselot P, Ffrench M, Marie JP, Archimbaud E. Thomas X, et al. Leukemia. 1999 Aug;13(8):1214-20. doi: 10.1038/sj.leu.2401474. Leukemia. 1999. PMID: 10450749 Clinical Trial.
Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemia.
Thomas X, Dombret H, Cordonnier C, Pigneux A, Gardin C, Guerci A, Vekhoff A, Sadoun A, Stamatoullas A, Fegueux N, Maloisel F, Cahn JY, Reman O, Gratecos N, Berthou C, Huguet F, Kotoucek P, Travade P, Buzyn A, de Revel T, Vilque JP, Naccache P, Chomienne C, Degos L, Fenaux P. Thomas X, et al. Leukemia. 2000 Jun;14(6):1006-13. doi: 10.1038/sj.leu.2401800. Leukemia. 2000. PMID: 10865965
Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group.
Fenaux P, Chevret S, Guerci A, Fegueux N, Dombret H, Thomas X, Sanz M, Link H, Maloisel F, Gardin C, Bordessoule D, Stoppa AM, Sadoun A, Muus P, Wandt H, Mineur P, Whittaker JA, Fey M, Daniel MT, Castaigne S, Degos L. Fenaux P, et al. Among authors: thomas x. Leukemia. 2000 Aug;14(8):1371-7. doi: 10.1038/sj.leu.2401859. Leukemia. 2000. PMID: 10942231 Clinical Trial.
448 results